Process for detecting a variant CD44 gene product
AssigneeBoehringer Ingelheim International GmbH
InventorsHelmut Ponta, Karl-Heinz Heider, Peter Herrlich, Steven T. Pals, Peter Dall
Life of this patent
Estimating the term…
Abstract
The invention relates to a process for diagnosing and analysing tumours which is based on detecting the expression of certain variant exons of the CD44-gene. Detection may be carried out at the protein or nucleic acid level. In a preferred embodiment the expression is detected in biopsy material using exon-specific antibodies. Thus, for example, v6-expression is a suitable prognostic parameter for breast cancer, the expression of a transitional epitope which is coded by exons v7 and v8 serves to diagnose cervical cancer.
Claims7
A process for detecting a product of the combined expression of variable exons v7 and v8 of a gene encoding CD44, comprising:
- (a) obtaining a human tissue sample;
- (b) contacting the tissue sample with an antibody, wherein the antibody binds an epitope on CD44 that is encoded by exons v7 and v8 together, the epitope being contained in SEQ. ID. NO:
- 9;
- and
- (c) detecting the antibody bound to the tissue sample.
An antibody that binds an epitope on CD44 that is encoded by exons v7 and v8 together, the epitope being contained in SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.